ReviewUrologic and male genital manifestations of granulomatosis with polyangiitis☆
Introduction
Granulomatosis with polyangiitis (Wegener's) (GPA) is an antineutrophil cytoplasmic antibody (ANCA)-associated multisystemic disease characterized by necrotizing granulomatous inflammation of the upper and lower respiratory tract and necrotizing vasculitis affecting predominantly small vessels [1], [2].
Worldwide, GPA is considered an uncommon disease, with annual incidence of 3–12 new cases per million inhabitants and prevalence of 22–157 cases per million [2], [3]. Mean age at diagnosis is between 45 and 60 years, but children can also be affected [3], [4].
Although GPA can virtually affect all body organs, urogenital involvement is rare. Large series of patients with this condition have reported < 1% of cases with evident signs at this level [5], [6], [7], [8], [9], [10]. In this sense, information regarding the urologic and genital manifestations of GPA is derived from case reports and in particular, from three small series [9], [11], [12].
The objectives of this review are: 1) to describe the main urological manifestations associated with GPA, 2) to detail bladder complications arising from cyclophosphamide exposure, the most widely used remission induction treatment for severe forms of ANCA-vasculitis and 3) to summarize current therapeutic options for GPA patients suffering from urogenital disease. Search in MEDLINE database for English language articles published between January 1970 and December 2014 was performed. Terms included were ANCA-associated vasculitis, small vessel vasculitis, granulomatosis with polyangiitis and Wegener's granulomatosis, in combination with keywords prostate, prostatitis, urethra, ureter, urethritis, hydronephrosis, epididymis, epididymitis, seminal vesicles, bladder, cystitis, renal mass, testis, orchitis, perineum, penis, cyclophosphamide, treatment adverse effects, treatment toxicity and cancer. Full text of relevant articles were retrieved and reviewed by all authors. In addition, late-breaking communications from international Rheumatology and Urology meetings celebrated during the past five years were reviewed. Gynecological manifestations of GPA are not detailed in this review.
Section snippets
General characteristics
Mean age of cases reported in the three larger studies detailing the characteristics of urogenital involvement in GPA was 56 years (range 21–77) [9], [11], [12]. These data are similar to that reported in general GPA cohorts [8], [10], [13], [14], [15].
Regarding clinical characteristics, when urogenital involvement was present, it was usually observed early, at disease onset (80%, as described in one series [9]). In GPA, urogenital tract symptoms are usually observed as part of generalized
Penis
Approximately 20 cases of patients with GPA involvement of the penis have been reported [18], [19], [20], [21], [22], [23]. In the series addressing urogenital involvement [9], [12], this organ was affected in 9–25% of patients. Ulceration was the presenting symptom in almost all cases, either at disease onset or during flares [11], [12]. These ulcers were usually painless, recurrent and in some cases accompanied by local edema and regional lymphadenopathy [9], [12], [18], [19], [20], [21], [22]
Urologic complications associated with cyclophosphamide treatment
Cyclophosphamide (in combination with glucocorticoids, GC) has classically been the cornerstone of treatment of severe forms of ANCA-associated vasculitis (AAV) [73]. Before the routine use of this drug, GPA caused the death of 90% of affected patients [16]. Now, this therapy induces remission in 75–90% of patients [7], [8], [74]. Unfortunately, chronic use of cyclophosphamide is associated with a number of side effects, some of them related to the urinary tract.
In particular, there is a clear
Treatment of urogenital involvement
Therapeutic approach of GPA urogenital disease can be divided into medical and surgical (interventional). According to data from specialized series [9], [11], [12], most patients have an excellent response to immunosuppressive therapy, with complete resolution of symptoms and low residual chronic morbidity. Surgical treatment is then reserved for acute situations requiring prompt solution, as in the case of acute urinary retention or for those patients with significant functional impairment,
Conclusions
Clinically evident genitourinary involvement is rare in GPA, although it can be the first manifestation of this disease. Differential diagnosis of these manifestations includes, in addition of disease activity, treatment-related adverse effects, infections and chronic damage, which should be accurately identified and treated. Combination of cyclophosphamide and glucocorticoids usually results in complete remission of vasculitis-related urogenital disease.
Conflict of interest statement
The authors declare no conflicts of interest.
Take-home messages
- •
Urogenital involvement is uncommon in GPA. Manifestations can include orchitis, cystitis, bladder fibrosis, urethral and ureteral stenosis, prostatitis, genital ulcers and kidney masses.
- •
High-cumulative cyclophosphamide doses are associated with an increased risk of bladder cancer and hemorrhagic cystitis.
- •
Genitourinary symptoms seem to be highly sensitive to glucocorticoids in combination with immunosuppressive drugs. Surgical procedures are rarely necessary.
References (98)
- et al.
Granulomatosis with polyangiitis (Wegener): clinical aspects and treatment
Autoimmun Rev
(2014) - et al.
Are anti-proteinase-3 ANCA a useful marker of granulomatosis with polyangiitis (Wegener's) relapses? Results of a retrospective study on 126 patients
Autoimmun Rev
(2014) - et al.
Wegener granulomatosis. Unusual cause of necrotizing urethritis
Urology
(1979) Vasculitis: a collection of pearls and myths
Rheum Dis Clin North Am
(2007)- et al.
Wegener's granulomatosis involving the prostate gland: report of a case
J Urol
(1966) - et al.
Prostatic involvement in Wegener's granulomatosis
Am J Kidney Dis
(1991) - et al.
Prostatic involvement in Wegener's granulomatosis
J Urol
(1987) - et al.
Wegener's granulomatosis involving prostate
Urology
(2005) - et al.
The clinical spectrum of granulomatous prostatitis: a report of 200 cases
J Urol
(1987) - et al.
Wegener granulomatosis: prostatic involvement and bladder outlet obstruction
Urology
(1989)
Isolated vasculitis of the bladder
Urology
Ureteral stenosis in Wegener's granulomatosis. Case report
Presse Med
Ureteral stenosis as the sole manifestation of Wegener's granulomatosis
Urology
Embolic testicular infarction secondary to nonbacterial thrombotic endocarditis in Wegener's granulomatosis
J Urol
Wegener granulomatosis presenting as epididymitis
Urology
Cyclophosphamide cystitis—identification of acrolein as the causative agent
Biochem Pharmacol
Squamous cell carcinoma of the bladder associated with cyclophosphamide therapy for Wegener's granulomatosis: a report of 2 cases
J Urol
2012 revised international chapel hill consensus conference nomenclature of vasculitides
Arthritis Rheum
Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis
Nephrol Dial Transplant
A 14-year-old boy with sore throat and tea-colored urine
Pediatrics
Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades
Arthritis Rheum
Wegener's granuloma. A series of 265 British cases seen between 1975 and 1985. A report by a sub-committee of the British Thoracic Society Research Committee
Q J Med
Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years
Ann Intern Med
Wegener granulomatosis: an analysis of 158 patients
Ann Intern Med
Urogenital manifestations in Wegener granulomatosis: a study of 11 cases and review of the literature
Medicine (Baltimore)
Urogenital manifestations of Wegener granulomatosis
Medicine (Baltimore)
Wegener's granulomatosis involving the urogenital tract
Br J Urol
Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety
Arthritis Rheum
A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies
N Engl J Med
An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients
Arthritis Rheum
Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis)
Br Med J
Wegener's granulomatosis diagnosed by testicular biopsy
Int Urol Nephrol
Glans penis ulceration revealing Wegener's granulomatosis
Dermatology
Wegener's granulomatosis of the penis: genital presentation of systemic disease
Dermatology
Wegener's granulomatosis of the penis: diagnosis and management
Can J Urol
Relapse of Wegener's granulomatosis presenting as a destructive urethritis and penile ulceration
Clin Rheumatol
A case of Wegener's granulomatosis with necrosis of the penis
Tohoku J Exp Med
Wegener's granulomatosis with urethral-penile location. Apropos of a case
Ann Urol (Paris)
Anti-MPO small-vessel vasculitis causing prostatis and nephritis
Clin Exp Nephrol
Wegener's granulomatosis of the prostate gland
Rheumatol Int
Wegener's granulomatosis presenting as prostate and submandibular gland disease
Sarcoidosis Vasc Diffuse Lung Dis
Wegener's granulomatosis presenting as prostatitis
Br J Urol
Wegener's granulomatosis presenting as lower back pain with prostatitis and ureteral obstruction
J Rheumatol
Wegener's granulomatosis with infiltration of the prostate
Br J Urol
Wegener's granulomatosis: prostatic involvement and recurrent urinary tract infections
BJU Int
Wegener's granulomatosis with prostatic involvement
Ann Dermatol Venereol
Wegener's granulomatosis: initial form of prostatic involvement
Rev Clin Esp
Prostatic involvement in Wegener's granulomatosis
Postgrad Med J
Wegener's granulomatosis presenting with gross hematuria due to prostatitis
Virchows Arch
Cited by (28)
Granulomatosis with poliangiitis mimicking testicular torsion
2023, Reumatologia ClinicaInitial presentation of granulomatosis with polyangiitis as urethral mass mimicking urethral cancer: A case report
2023, Case Reports in Women's HealthCurrent clinical and therapeutic approach to tumour-like mass lesions in granulomatosis with polyangiitis
2022, Autoimmunity ReviewsCitation Excerpt :According to some Authors [70], GPA seems to confer a higher risk of developing renal cancer (8.7 times) when compared with other autoimmune diseases irrespective of cyclophosphamide effects. Thus, a neoplastic process of kidney has to be ruled out by a histologic examination [70,103]. Benign disease should also be ruled out, including inflammatory myofibroblast tumour, xanthogranulomatous pyelonephritis and malakoplakia [74].
Recurrent obstructive prostatitis revealing granulomatosis with polyangiitis
2022, Urology Case ReportsCitation Excerpt :In contrast, genito-urinary disease is rare in GPA patients, reported in <1% of cases in large cohorts. Manifestations at this level include prostatitis, destructive urethritis, genital ulcers, orchitis and renal masses.1 We report herein the case of a 46-old immunocompetent patient presenting for recurrent urinary tract infections (UTI) revealing GPA.
Rapidly recurrent prostatic obstruction due to granulomatosis with polyangiitis
2021, Urology Case ReportsCitation Excerpt :This combination is generally successful and leads to disease remission in most cases.2 More recently rituximab in combination with prednisone has also proven to be effective.2 As GPA was not apparent at presentation the patient initially received surgical rather than medical therapy.
An abscessed granulomatous prostatitis
2020, Revue de Medecine Interne
- ☆
MA Alba was supported by Consejo Nacional de Ciencia y Tecnología (CONACyT 309320), Mexico and by the Agencia de Gestió d'Ajuts Universitaris i de Recerca (AGAUR, Generalitat de Catalunya). MC Cid was supported by Ministerio de Economía y Competitividad (SAF 2014/ 57708-R).